Equity Details
Price & Market Data
Price: $30.66
Daily Change: +$1.38 / 4.50%
Daily Range: $28.61 - $31.46
Market Cap: $355,973,984
Daily Volume: 84,670
Performance Metrics
1 Week: -6.07%
1 Month: 2.68%
3 Months: 34.27%
6 Months: 151.3%
1 Year: 283.3%
YTD: 35.66%
About Surrozen, Inc. (SRZN)
Summarized market data for Surrozen, Inc. (SRZN). Price: 30.66, daily change: +$1.38 / 4.50%. Market cap: 355,973,984. Performance over 3-month and 6-month periods.
Company Details
Employees: 44
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Surrozen, Inc., a biotechnology company, discovers and develops product candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the eye, intestine, liver, lung, retina, kidney, cochlea, cornea, skin, pancreas, and central nervous system. The company develops SZN-814, which combines Frizzled 4 (Fzd4 agonism) and vascular endothelial growth factor (VEGF antagonism) to treat diabetic macular edema (DME), neovascular age-related macular degeneration (wet AMD), and retinopathy indications; SZN-8143, which combines Fzd4 agonism, VEGF antagonism, and interleukin-6, or IL-6 for the treatment of DME/wet AMD/uveitic macular edema; and SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has a collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies; and a research collaboration agreement with TCGFB, Inc. to discover antibody therapeutics targeting transforming growth factor beta, or TGF-ß, for the treatment of patients with idiopathic pulmonary fibrosis. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California.